M. A. Gertz

1.3k total citations
19 papers, 932 citations indexed

About

M. A. Gertz is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, M. A. Gertz has authored 19 papers receiving a total of 932 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Hematology and 8 papers in Oncology. Recurrent topics in M. A. Gertz's work include Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers), Multiple Myeloma Research and Treatments (8 papers) and Cancer Treatment and Pharmacology (5 papers). M. A. Gertz is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers), Multiple Myeloma Research and Treatments (8 papers) and Cancer Treatment and Pharmacology (5 papers). M. A. Gertz collaborates with scholars based in United States and Italy. M. A. Gertz's co-authors include Robert A. Kyle, Angela Dispenzieri, S. Vincent Rajkumar, Rafaël Fonseca, Martha Q. Lacy, John A. Lust, Thomas E. Witzig, Philip R. Greipp, Tracy L. Leong and Mark R. Litzow and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Nephrology Dialysis Transplantation.

In The Last Decade

M. A. Gertz

19 papers receiving 917 citations

Peers

Countries citing papers authored by M. A. Gertz

Since Specialization

Citations

This map shows the geographic impact of M. A. Gertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. A. Gertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. A. Gertz more than expected).

Fields of papers citing papers by M. A. Gertz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. A. Gertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. A. Gertz. The network helps show where M. A. Gertz may publish in the future.

Co-authorship network of co-authors of M. A. Gertz

This figure shows the co-authorship network connecting the top 25 collaborators of M. A. Gertz. A scholar is included among the top collaborators of M. A. Gertz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. A. Gertz. M. A. Gertz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial. 2011 ·Journal of Clinical Oncology ·Francis K. Buadi, (unknown), Angela Dispenzieri, Betsy LaPlant, (unknown), G. S. Nowakowski, S. R. Hayman, Kristen Detweiler Short, David Dingli, M. A. Gertz, Philip R. Greipp, John A. Lust, Thomas E. Witzig, Stephen R. Zeldenrust, Stephen J. Russell, S. Vincent Rajkumar, Shaleen Kumar	1
2	Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory multiple myeloma (MM). 2010 ·Journal of Clinical Oncology ·M. Q. Lacy, M. A. Gertz, S. R. Hayman, Angela Dispenzieri, (unknown), (unknown), A. Keith Stewart, Jake Allred, (unknown), S. Vincent Rajkumar	3
3	A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis. 2010 ·Journal of Clinical Oncology ·Angela Dispenzieri, M. A. Gertz, S. R. Hayman, Shaji Kumar, Craig B. Reeder, Stephen R. Zeldenrust, Jake Allred, (unknown), Francis K. Buadi, (unknown)	3
4	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis 2009 ·Haematologica ·Alan H. Bryce, Rhett P. Ketterling, M. A. Gertz, (unknown), Ryan A. Knudson, Stephen R. Zeldenrust, Sanjay Kumar, (unknown), (unknown), Robert A. Kyle, PR Greipp, John A. Lust, Stephen J. Russell, S. Vincent Rajkumar, Rafaël Fonseca, Angela Dispenzieri	71
5	Long-term outcome of autologous stem cell transplantation in light chain deposition disease 2008 ·Nephrology Dialysis Transplantation ·Elizabeth C. Lorenz, M. A. Gertz, Fernando C. Fervenza, Angela Dispenzieri, M. Q. Lacy, S. R. Hayman, (unknown), Nelson Leung	65
6	High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma 2008 ·Journal of Clinical Oncology ·Lijo Simpson, S. Vincent Rajkumar, Angela Dispenzieri, M. Q. Lacy, S. R. Hayman, Vivek Roy, Keith Stewart, M. A. Gertz, Philip R. Greipp, Shaleen Kumar	6
7	Association of translocation t(11;14) with survival in patients with light chain (AL) amyloidosis 2008 ·Journal of Clinical Oncology ·Alan H. Bryce, (unknown), M. A. Gertz, Robert A. Kyle, Stephen R. Zeldenrust, (unknown), Suzanne R. Hayman, Francis K. Buadi, Rafaël Fonseca, Ryan A. Knudson, Angela Dispenzieri	1
8	Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma 2006 ·Bone Marrow Transplantation ·Francis K. Buadi, Ivana N. Micallef, Stephen M. Ansell, Luis F. Porrata, Angela Dispenzieri, (unknown), D A Gastineau, M. A. Gertz, Martha Q. Lacy, Mark R. Litzow, Ayalew Tefferi, David J. Inwards	40
9	Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia 2006 ·Bone Marrow Transplantation ·M. A. Elliott, Ayalew Tefferi, WJ Hogan, Louis Letendre, D A Gastineau, Stephen M. Ansell, Angela Dispenzieri, M. A. Gertz, S. R. Hayman, David J. Inwards, (unknown), (unknown), Luis F. Porrata, Mark R. Litzow	47
10	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma 2004 ·Bone Marrow Transplantation ·Shaji Kumar, Martha Q. Lacy, Angela Dispenzieri, S. Vincent Rajkumar, Rafaël Fonseca, Susan M. Geyer, Cristine Allmer, Thomas E. Witzig, John A. Lust, Philip R. Greipp, Robert A. Kyle, Mark R. Litzow, M. A. Gertz	40
11	Long-term analysis of the palliative benefit of 2-Chlorodeoxyadenosine (2-CdA) for myelofibrosis with myeloid metaplasia 2004 ·Journal of Clinical Oncology ·(unknown), Ruben A. Mesa, M. A. Gertz, Ayalew Tefferi	1
12	Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma 2003 ·Bone Marrow Transplantation ·(unknown), Ivana N. Micallef, David J. Inwards, Stephen M. Ansell, G Dewald, Angela Dispenzieri, D A Gastineau, M. A. Gertz, (unknown), Curtis A. Hanson, Martha Q. Lacy, Ayalew Tefferi, Mark R. Litzow	40
13	The effect of respiration on left ventricular diastolic filling as assessed by radionuclide ventriculography 2000 ·Nuclear Medicine Communications ·Ian P. Clements, Lyle J. Olson, Paul D. Scanlon, M. A. Gertz, C. J. Mullany	4
14	A multicenter phase II trial of 4'-IODO-4'-deoxydoxorubicin (IDOX) in primary amyloidosis (AL) 2000 ·M. A. Gertz, (unknown), Angela Dispenzieri, Bruce D. Cheson, Bart Barlogie, Robert A. Kyle, Giovanni Palladini, (unknown), Giampaolo Merlini	1
15	Prognostic value of bone marrow angiogenesis in multiple myeloma. 2000 ·PubMed ·S. Vincent Rajkumar, Tracy L. Leong, (unknown), Rafaël Fonseca, Angela Dispenzieri, Martha Q. Lacy, John A. Lust, Thomas E. Witzig, Robert A. Kyle, M. A. Gertz, Philip R. Greipp	270
16	Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma 1999 ·Bone Marrow Transplantation ·S. Vincent Rajkumar, Rafaël Fonseca, MQ Lacy, TE Witzig, (unknown), PR Greipp, (unknown), RA Kyle, MR Litzow, M. A. Gertz	40
17	Hepatic Amyloidosis: Clinical Appraisal in 77 Patients 1997 ·Hepatology ·M. A. Gertz, Robert A. Kyle	64
18	Secondary Systemic Amyloidosis (AA): Response and Survival in 64 Patients 1991 ·PubMed ·M. A. Gertz, Robert A. Kyle	233
19	A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer 1984 ·American Journal of Clinical Oncology ·Joseph Rubin, Allan J. Schutt, M. J. OʼConnell, M. A. Gertz, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact